The adverse effects of AKT activation in the stroma can be counteracted by IL1B through down-regulation of the KGF receptor and so in cancer a balance between the pro-invasive AKT and KGF pathway and the anti-invasive IL1B levels within the stroma will drive the epithelium to either a more or less aggressive phenotype. The gene discussed is AKT1; the disease is cancer.